Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 +1.42%70 FCF Margin % is 11.17% as of Apr. 2026, which is 28% below its 10-year median of 15.59. GuruFocus rates TSE:4880 with a GF Score™ of 70/100 and a GF Value™ of 円777.65 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 957 Biotechnology companies, CellSource Co ranks better than 81.19% on this metric.
The historical data trend for CellSource Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, CellSource Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where CellSource Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a FCF Margin % of 11.17% as of Apr. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CellSource Co and its competitors. This is 28% below median its historical median of 15.59. Over the past decade, CellSource Co's FCF Margin % has ranged from 1.19 to 28.63. According to the industry distribution chart, CellSource Co ranks #180 out of 957 companies in the Biotechnology industry, placing it in the top 18.8%.
Is CellSource Co's FCF Margin % too high?
CellSource Co's current FCF Margin % of 11.17% is 28% below median its 10-year median of 15.59. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 28.63. Based on the distribution chart, CellSource Co ranks #180 out of 957 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #180 out of 957 companies for FCF Margin %. This places CellSource Co in the top 19% of its industry — outperforming the majority of peers. Historically, CellSource Co's own FCF Margin % has ranged from 1.19 to 28.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CellSource Co and its competitors. CellSource Co's current FCF Margin % is 11.17%, which is 28% below median its own 10-year median of 15.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円777.65, compared to a current price of 円356.00 — trading 54.2% below its estimated fair value. The current FCF Margin % is 11.17%, which is 28% below median its 10-year median of 15.59. CellSource Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current FCF Margin % is 11.17% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円356.00 is trading 54.2% below its estimated GF Value™ of 円777.65.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
FCF Margin %: 11.17% (28% below median its 10-year median of 15.59)
GF Value™: 円777.65 vs. price of 円356.00 (54.2% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
70GF Score
Get the complete analysis for TSE:4880
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
